

Bakers' Yeast Mediated Stereo Selective Reduction of Cis (+) Diketolactam to Cis (+) Hydroxylactam, a Key Intermediate for Diltiazem Synthesis in a Laboratory Scale Bioreactor

Pradipta Tokdar, Prafull Ranadive, Saji George, Abhay Upare, Sandesh Vishwasrao, Mita Roy, and Hariharan Sivaramakrishnan

Abstract—The reduction of (RS)-2-(4-methoxyphenyl)-1,5-benzothiazepin-3,4(2H,5H)-dione[(RS)-1] to (2S,3S)-2,3-dihydro-3-hydroxy-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one using bakers' yeast was carried out in the laboratory scale 10L fermenter. Under optimum reaction conditions, 200g of substrate was reduced to desired chiral intermediate in 4L reaction volume with 79.33% of conversion within 89h. The optimum conditions for the effective reduction were at pH 6.5 and at 30 °C temperature. The crystals of desired isomer were isolated from the reaction mixture with the total yield of 42%, having 95.42% of assay purity with 99.80% of enantiomeric excess.

Index Terms— Asymmetric reduction, bakers' yeast, bioconversion, diltizem hydrochloride.

I. INTRODUCTION

Diltiazem hydrochloride is a representative calcium channel blocker that is used clinically as an effective antianginal and antihypertensive agent throughout the world. It is 1,5-benzothiazepine derivative with two asymmetric carbon atoms at C-2 and C-3 position. Among the possible diastereomers, the (2S,3S)-isomer exhibits strong coronary vasodilating activity. Therefore, stereoselective synthesis of the (2S,3S)-isomer has been attracting great attention. Commercially, diltiazem has been produced by a classical resolution process [1]. A number of studies have been reported on the stereoselective synthesis of diltiazem hydrochloride: chemical optical resolution [2]-[3], asymmetric dihydroxylation [4], asymmetric hydrocyanation [5], Darzens reaction [6], Michael addition [7], asymmetric reduction [8] and enzymatic asymmetric hydrolysis [9] - [10]. In this process the yield of desired isomer does not exceed 50%, thereby generating enormous waste containing (2RS,3RS)-2-hydroxy-3-(4-methoxyphenyl)-3-(2-aminop

henylthio) propionic acid. So, for favorable process economics, recycling of the waste enantiomer is essential. This was achieved by oxidizing the alcohol moiety (chiral centre) in the waste (mother liquor after resolution) to ketone, (RS)-2-(4-methoxyphenyl)-1,5-benzothiazepin-3,4(2H,5H)-dione and stereo specific reduction of ketone to form the desired (2S,3S)-2,3-dihydro-3-hydroxy-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one.

The chemo enzymatic synthesis of one of the diltizem chiral intermediate [(-)-MPGM] has been achieved by lipase mediated biocatalytic resolution of racemic *trans*-3-(4'-methoxyphenyl) glycidic acid methyl ester [(±)-MPGM] using immobilized enzyme system [11]. Stereo selective reduction of ketone to the desired isomer has been extensively studied from the viewpoint of their high efficiency. The chemical reduction of ketone using chiral reducing agent NaBH₄-(S)-(tert)-leucine has been reported to give only 86% yield. The biochemical asymmetric reduction of the prochiral ketone was reported [12] with a conversion yield of 92-94% using bakers' yeast in a small reaction volume of 3ml during a screening experiment. One-paper reports about the bakers' yeast mediated bioreduction of prochiral ketones using ethanol as an energy source [13]. It was further investigated for industrial application at shake flask level by which 100g of substrate was reduced in 1L reaction volume to produce desired intermediate in 80% yield [14]. Nevertheless there is no report on the bioreduction using a waste recycling process at flask or fermenter level for the production of Diltizem [15].

The present study deals with the optimization of bakers' yeast mediated stereo-selective reduction of acid waste to desired isomer in a laboratory scale fermenter. We have made an attempt to reduce 200g of substrate in 4L reaction volume using Meteoric- instant dry yeast as a source of bakers' yeast. The process conditions for the optimal bioconversion have been described and the desired isomer was isolated in pure form from the reaction mixture.

II. MATERIALS & METHODS

A. Strain

Bakers' instant dry yeast from Meteoric, Mumbai was

Manuscript received June 24, 2011; revised December 18, 2011.

Pradipta Tokdar, Prafull Ranadive and Saji George is in Fermentation Technology Lab, Natural Products Department.

Abhay Upare, Sandesh Vishwasrao, Mita Roy, and Hariharan Sivaramakrishnan is in Innovations Group, Synthetic Lab. Piramal Life Sciences Ltd, 1, Nirlon Complex, Off Western Express Highway, Goregaon (East), Mumbai-400063, India.(e-mail:pradipta.tokdar@piramal.com.)

procured and used for the study. We have screened different yeast strain for this biotransformation in the flask and finally selected Meteoric- instant dry yeast which showed better conversion, for the optimization study in fermenter.

B. Bioconversion Study in Shake Flask:

Initially the bioconversion was standardized in the shake flask with respect to the concentration of substrate, buffer pH and amount of yeast inoculum. The reaction mixture consists of 34ml of phosphate buffer and yeast inoculum, which was added to 1L Erlenmeyer flask and incubated on rotary shaker at 150rpm at 30 °C. A 3.84ml of 50% dextrose monohydrate solution was fed to the flask after every 24h starting from zero hour. A substrate dissolved in 6ml of dimethyl formamide (DMF) was added to the reaction mixture with the intermittent addition of 500µl at a time within 36h. After 120h, the reaction was terminated and the substrate and product was extracted as mentioned C.

C. Estimation of Product from Reaction Mixture:

10ml of reaction mixture was centrifuged at 5000rpm for 30min to separate biomass-containing product and supernatant was discarded. The sediment was extracted with 10ml of dichloromethane (CH₂Cl₂) and then centrifuged at 5000rpm for 30min to get the organic layer. The sediment was further extracted with same volume of CH₂Cl₂ and centrifuged. The organic layer was pooled together and concentrated to dryness using rotary evaporator at 45 °C and analyzed by HPLC as mentioned in D.

D. Analytical Methods:

HPLC: HPLC analysis was performed on an Agilent series 1100 Liquid Chromatograph and equipped with a quaternary pump system. The mobile phase consists of H₂O (0.05% TFA)/CH₃CN (0.05% TFA)=60/40 (v/v), with a flow rate of 1ml/min. The column used was 4.6mmx250mm. Temperature was 40 °C and detection was at 220nm. Their retention times were 7.1min for [(RS)-1] and 6.1min for (2S, 3S)-2.

Chiral HPLC: Chiral HPLC analysis was performed on an Agilent series 1050, the column was chiralpak OD and equipped with a quaternary pump system. The mobile phase consists of Heptane/C₂H₅OH=90/10 (v/v), with a flow rate of 1ml/min. The column used was 4.6mmx250mm. Temperature was 30 °C and detection was at 250nm. Their retention times were 15.2min for l-hydroxylactam and 24.7min for d-Hydroxylactam.

E. Bioconversion Studies in Bioreactor:

The bioconversion studies were carried out in New Brunswick Scientific, USA (NBS) fermenter having a geometric volume of 10L. The fermenter was initially dry sterilized and condensate water was aseptically drained. A 3.6L of 100mM sterile phosphate buffer (pH 6.5) along with the 200g of instant dry yeast was aseptically transferred to the fermenter. The temperature was set at 30 °C and agitation at 500rpm. The pH of the reaction was continuously maintained at 6.5 using 5M NaOH in auto-control mode. Dextrose monohydrate (50% solution) was fed to the fermenter with a flow rate of 14.58ml/h from the beginning till 74h and afterwards it was increased to 23.33ml/h till 89h. Towards

the end, after 89h the flow rate was maintained with 14.58ml/h till end of the reaction. The 200g of [(RS)-1] was dissolved in 400ml of DMF and added to the reaction mixture in the fermenter at the rate of 9.52ml/h from time zero to 42h. Samples were withdrawn from the fermenter at regular time interval and processed as mentioned in C for analysis. The reaction was continued till 97h.

F. Isolation of (2S,3S)-2 from the Reaction Mixture:

The reaction mixture from the fermenter was centrifuged at 5000rpm for 30min and the supernatant was discarded. The pellet was extracted with 6L of CH₂Cl₂ and then centrifuged at 5000rpm for 30min to get the organic layer. The pellet was further extracted with same volume of CH₂Cl₂ and centrifuged. The organic layer was pooled together and concentrated to dryness using rotary evaporator at 45 °C. The CH₂Cl₂ extract was refluxed twice in toluene (C₆H₅CH₃) and filtered. The filtrate was pooled and chilled to 0-5 °C and further filtered to recover the solid product.

III. RESULTS AND DISCUSSION

The Diltiazem hydrochloride synthesis starting from p-anisaldehyde is shown in fig 1. In this process, the racemic mixture of acid is formed out of which around 50% contributes to the cis-1(-) acid, which is a waste product. For the effective utilization of this waste, it was reduced to [(RS)-1] using chemical synthesis, which was then used as a starting substrate for bioconversion to (2S, 3S)-2 in the present study.




Fig. 1. Synthesis of diltiazem hydrochloride by synthetic and biological route.

Stereo selective reduction of ketone to the desired isomer has been reported. In this paper we report the reduction of [(RS)-1] to the desired isomer (2S, 3S)-2 using biotransformation catalyzed by whole cells of bakers' yeast. Reports are there where various microorganisms were

screened to carry out the reduction of [(RS)-1] to the desired isomer. They observed that the reduction by various organisms produced a mixture of stereoisomer with that (2S, 3S)-2 stereoisomer being the major product.

The bakers' yeast was found to give the highest conversion yield and excellent stereo selectivity for the production of (2S, 3S)-2 isomer. Diltiazem synthesis through asymmetric reduction by bakers' yeast compares favorably with that through optical resolution by lipase as a synthetic route. In the present work initially we screened different brands of bakers' yeast in shake flask to find out the best strain for bioconversion. Out of different lots tested, the Meteoric brand dried yeast was found to be the best and hence was used for further studies.

Different trials were taken in the flask to find out the optimum conditions for desired bioconversion. Table (I) describes the conversion obtained with varying conditions like yeast cell concentration, substrate concentration, glucose dosing, pH of the buffer and temperature. The optimum conversions were around with the buffer pH 6.5, temperature 30 °C and substrate concentration 50g/L under shake flask condition. Shake flask studies have many limitations as the feed rate cannot be controlled and the continuous maintenance of pH is very difficult. Hence these conditions were used for scale up studies in laboratory scale fermentor.

The large-scale production of Diltiazem intermediates has been reported using an aggregate of [(RS)-1], which was reduced by bakers' yeast under shake flask cultivation. The author described the difficulty of the bakers' yeast mediated reduction of [(RS)-1] for industrial application due to low substrate concentration.

Hence to improve the product concentration, different procedures of substrate addition were followed like use of aggregates prepared from crystals of [(RS)-1] or DMF soluble substrates.

While using DMF as a vehicle for substrate delivery to the reaction mixture, there is a possibility that a large amount of DMF may inactivate yeast cells and thereby inhibit reduction. Hence a fed batch operation using a DMF solution of [(RS)-1] was reported for large scale production of (2S,3S)-2 at a shake flask level. However, there are no reports on this bioconversion at the laboratory scale fermentor level.

In the present study DMF soluble substrate [(RS)-1] was reduced under fed batch conditions using Meteoric bakers' yeast. The DMF soluble substrate was slowly added to the reaction mixture at the rate of 9.52ml/h and the entire 200g substrate addition was completed by 42h.

The slow substrate addition helped in the formation of the desired product with better conversion efficiency. After complete addition of the substrate, there was an increase in DMF concentration in the reaction mixture, which lowered the conversion efficiency. The continuous maintenance of pH and dextrose dosing helped in maintaining the viability of cells, thereby achieving further improvement in bioconversion after 74h. By 89h the maximum conversion of 79.33% was obtained and hence the reaction was terminated by 97h. Fig 2 and 3 shows the HPLC chromatogram of initial substrate [(RS)-1] and converted product (2S, 3S)-2 respectively. HPLC chromatogram of the sample from the reaction mixture after 2h is shown in Fig 4, which indicates

the beginning of the bioconversion with the formation of (2S, 3S)-2. Towards the end of the reaction at 89h, the maximum conversion of substrate to desired isomer is seen from the HPLC chromatogram in Fig 5.

This process could be further optimized to get improvements in bioconversion efficiency. The attempts were made to isolate the crystals of cis (+) hydroxylactam from the reaction mixture. The initial input of the substrate was 200g and with 79.33% conversion the expected yield of the product was 159g as shown in Fig 6. The isolation procedure that was followed could be able to yield 66.78g of desired product with 42% purification efficiency. The separation efficiency could be further improved for achieving higher yields.

TABLE I: SHAKE FLASK TRIALS

Varying Parameters					HPLC (Area%)	
Dried yeast (g/L)	Substrate (g/L)	Dextrose dosed (ml/h)	Buffer pH	Temperature	Hydroxy Lactam	Diketo Lactam
100	75	1.92	6.5	30	15.59	78.67
150	75	1.92	6.5	30	15.9	76.42
200	75	1.92	6.5	30	16.75	73.94
250	75	1.92	6.5	30	16.98	72.5
100	50	1.92	6.5	30	53.77	39.44
100	50	1.92	6.5	25	24.85	75.06
100	50	1.92	5	30	8.71	82.89
100	50	1.92	7.6	30	30.33	62.06
100	50	3.84	6.5	30	17.5	75.32




Fig 2. Initial substrate [(RS)-1]




Fig 3. Final product [(2S, 3S)-2]




Fig 4. Reaction mixture at 2h




Fig 5. Reaction mixture at 89h




Fig 6. In-process analysis.

IV. CONCLUSION

The reduction of (RS)-2-(4-methoxyphenyl)-1, 5-benzothiazepin-3,4(2H,5H)-dione[(RS)-1] recovered from the oxidation of alcohol from effluent mother liquor using bakers' yeast was successfully demonstrated in a laboratory scale 10L fermenter. The maximum conversion of 79.33% was observed in this study within 89h of reaction using 200g of substrate. The desired intermediate was isolated from the reaction mixture with 42% of recovery having 95.42% of assay purity with 99.80% of enantiomeric excess.

REFERENCES

[1] Y. Yamada, Mori, K. Morimatsu, Y. Ishizu, Y. Ozaki, R. Yos hioka, T. Nakatani, and H. Seko. *J. Org. Chem.* 61, 8586- 8590. 1996.
 [2] H. Iouue, S. Takeo, M. Kawazu, and H. Kugita. Synthesis of 1, 5-b enzothiazepine derivatives. IV. Resolution of dl-cis-3- acetoxo-5-[2-(dimethylamino) ethyl]-2, 3-dihydro-2-(p- meth

oxyphenyl)-1, 5-benzothiazepin-4(5H)-on hydrochloride. *Yak -ugaku Zasshi*, 93, 729-732 (in Japanese). 1973
 [3] M. Senuma, M. Sbibazaki, S. Nishimoto, K. Shibata, K. Oka mura, and T. Date. The practical resolution of (2RS, 3RS)-2- hydroxy-3-(4-methoxyphenyl)-3-(2-nitrophenylthio)propionic acid, a key intermediate for diltiazem, with L-lysine. *Chem. Pharm.Bull.* 37, 3204-3208 ,1989.
 [4] K. G. Watson, Y. M. Fung, M. Gredley, G. J. Bird, W. R. Jack- son, H. Gountzos, and B. R. Matthews.: *Asymmetric syntheses of (+)- diltiazem hydrochloride.* *J.Chem. Soc. Chem. Co -mmun*, 1018-1019, 1990.
 [5] B. R. Matthews, H. Gountzos, W. R. Jackson, and K.G. Wats -on *Synthesis of threo-3-aryl-2,3-dihydroxypropanoic acid d -erivatives with high optical purity.* *Tetrahedron Lett.* 30, 51 57-5158 (1989).
 [6] A. Schwartz, P.B. Madan, E. Mohacsi, J.P. O'Brien, L.J. To -daro, and Coffen. D. L. Enantioselective synthesis of calcium channel blockers of the diltiazem group. *J. Org. Chem.* 57, 8 51-856 (1992).
 [7] O. Miyata, T. Shinada, I. Ninomiya, and T. Naito. Asymmetri -c induction at two contiguous stereogenic centers by diastere -oface differentiating nucleophilic addition reaction. *Tetrahed -ron Lett.* 32, 3519-3522 .1991.
 [8] K. Matsuki, M. Sobukawa, A. Kawai, H. Inoue, and M.Taked -a. Asymmetric reduction of aromatic ketones. II. An enantios electve synthesis of methyl (2R, 3S)-3-(4-methoxyphenyl) gl -ycidate. *Chem. Pharm. Bull.* 41, 643-648 .1993.
 [9] H. Akita, Y. Enoki, H. Yamada, and T. Oishi. Enzymatic hyd -rolysis in organic solvents for kinetic resolution of water in -ouble α -acyloxy esters with immobilized lipases. *Chem. Pha -rm. Bull.* 37, 2876-2878 1989.
 [10] H. Akita, I. Umezawa, H. Matsukura, and T. Oisbi. A lipid- lipase aggregate as a new type of immobilized enzyme. *Che -m. Pharm. Bull.* 39, 1632-1633 (1991).
 [11] L. L. Zhao, J. Pan, and J. H Xu.: Efficient Production of Dilt-iazem Chiral Intermediate using Immobilized Lipase from *Serratia Marcescens.* *Biotechnology and Bioprocess Engin -eering* 15: 199-207 (2010).
 [12] H. Matsumae, H. Douno, S. Yamada, T. Nishida, Y. Ozaki, T. Shibatani, and T. Tosa. *Journal of Fermentation and Bioeng -ineering*, Vol. 79, No. 1, 28-32, 1995.
 [13] T. Kometani, E. Kitatsuji, and R. Matsuno: Bakers' yeast mediated bioreduction. A new procedure using ethanol as an energy source. *Chem. Lett.* 1465-1466.1989.
 [14] T. Kometani, Y. Sakai, H. Matsumae, T. Shibatani, and R. Mats -uno. *Journal of Fermentation and Bioengineering*, Vol 84, No. 3, 195-199, 1997.
 [15] T. Kometani, H. Yoshii, Y. Takeuchi, and R. Matsuno.: La -rge scale preparation of (R) -1,2-propanediol through bake -rs' yeast-mediated bioreduction. *J. Ferment. Bioeng.* 76, 414-415 .1993.

Mr. Pradipta Tokdar is born in Kolkata on 8th December 1980. He completed his Bachelor in Pharmacy from College of Pharmaceutical Sciences, Mohuda, Berhampur, Orissa, India, in 2004 and Master in Technology (Biotechnology) from Vellore Institute of technology, VIT University, Vellore, Tamil Nadu, India in 2007. Currently he is pursuing his PhD (Biotechnology) from Vellore Institute of Technology, VIT University, Vellore, Tamil Nadu, India. His reseach interest areas are Bioprocess Technology and Biotransformation.



He has 4 years industrial experience. He is currently working as a Junior Research Scientist in Fermentation Technology Lab, Natural Products Department in Piramal Life Sciences Ltd. He is a member of Asia-Pacific Chemical, Biological and Environmental Engineering Society (APCBES) and Society for Biotechnologists (India). He has two international publications of research papers.